Literature DB >> 27018254

Trends in primary central nervous system lymphoma incidence and survival in the U.S.

Meredith S Shiels1, Ruth M Pfeiffer1, Caroline Besson2, Christina A Clarke3, Lindsay M Morton1, Leticia Nogueira4, Karen Pawlish5, Elizabeth L Yanik1, Gita Suneja6, Eric A Engels1.   

Abstract

It is suspected that primary central nervous system lymphoma (PCNSL) rates are increasing among immunocompetent people. We estimated PCNSL trends in incidence and survival among immunocompetent persons by excluding cases among human immunodeficiency virus (HIV)-infected persons and transplant recipients. PCNSL data were derived from 10 Surveillance, Epidemiology and End Results (SEER) cancer registries (1992-2011). HIV-infected cases had reported HIV infection or death due to HIV. Transplant recipient cases were estimated from the Transplant Cancer Match Study. We estimated PCNSL trends overall and among immunocompetent individuals, and survival by HIV status. A total of 4158 PCNSLs were diagnosed (36% HIV-infected; 0·9% transplant recipients). HIV prevalence in PCNSL cases declined from 64·1% (1992-1996) to 12·7% (2007-2011), while the prevalence of transplant recipients remained low. General population PCNSL rates were strongly influenced by immunosuppressed cases, particularly in 20-39 year-old men. Among immunocompetent people, PCNSL rates in men and women aged 65+ years increased significantly (1·7% and 1·6%/year), but remained stable in other age groups. Five-year survival was poor, particularly among HIV-infected cases (9·0%). Among HIV-uninfected cases, 5-year survival increased from 19·1% (1992-1994) to 30·1% (2004-2006). In summary, PCNSL rates have increased among immunocompetent elderly adults, but not in younger individuals. Survival remains poor for both HIV-infected and HIV-uninfected PCNSL patients.
© 2016 John Wiley & Sons Ltd.

Entities:  

Keywords:  Lymphoma; central nervous system; human immunodeficiency virus; incidence; survival; transplant

Mesh:

Year:  2016        PMID: 27018254      PMCID: PMC4961566          DOI: 10.1111/bjh.14073

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   8.615


  23 in total

Review 1.  Lymphomas occurring specifically in HIV-infected patients: from pathogenesis to pathology.

Authors:  Annunziata Gloghini; Riccardo Dolcetti; Antonino Carbone
Journal:  Semin Cancer Biol       Date:  2013-08-30       Impact factor: 15.707

2.  Proportions of Kaposi sarcoma, selected non-Hodgkin lymphomas, and cervical cancer in the United States occurring in persons with AIDS, 1980-2007.

Authors:  Meredith S Shiels; Ruth M Pfeiffer; H Irene Hall; Jianmin Li; James J Goedert; Lindsay M Morton; Patricia Hartge; Eric A Engels
Journal:  JAMA       Date:  2011-04-13       Impact factor: 56.272

3.  Risk of non-Hodgkin lymphoma subtypes in HIV-infected people during the HAART era: a population-based study.

Authors:  Todd M Gibson; Lindsay M Morton; Meredith S Shiels; Christina A Clarke; Eric A Engels
Journal:  AIDS       Date:  2014-09-24       Impact factor: 4.177

4.  Posttransplant lymphoproliferative disorder: significance of central nervous system involvement.

Authors:  J F Buell; T G Gross; M J Hanaway; J Trofe; P Roy-Chaudhury; M R First; E S Woodle
Journal:  Transplant Proc       Date:  2005-03       Impact factor: 1.066

5.  Survival among patients with primary central nervous system lymphoma, 1973-2004.

Authors:  Andrew D Norden; Jan Drappatz; Patrick Y Wen; Elizabeth B Claus
Journal:  J Neurooncol       Date:  2010-06-17       Impact factor: 4.130

6.  Trends in cancer risk among people with AIDS in the United States 1980-2002.

Authors:  Eric A Engels; Ruth M Pfeiffer; James J Goedert; Phillip Virgo; Timothy S McNeel; Steven M Scoppa; Robert J Biggar
Journal:  AIDS       Date:  2006-08-01       Impact factor: 4.177

7.  Population-based surveillance of HIV-associated cancers: utility of cancer registry data.

Authors:  Christina A Clarke; Sally L Glaser
Journal:  J Acquir Immune Defic Syndr       Date:  2004-08-15       Impact factor: 3.731

8.  Cancer risk in people infected with human immunodeficiency virus in the United States.

Authors:  Eric A Engels; Robert J Biggar; H Irene Hall; Helene Cross; Allison Crutchfield; Jack L Finch; Rebecca Grigg; Tara Hylton; Karen S Pawlish; Timothy S McNeel; James J Goedert
Journal:  Int J Cancer       Date:  2008-07-01       Impact factor: 7.396

9.  Spectrum of cancer risk among US solid organ transplant recipients.

Authors:  Eric A Engels; Ruth M Pfeiffer; Joseph F Fraumeni; Bertram L Kasiske; Ajay K Israni; Jon J Snyder; Robert A Wolfe; Nathan P Goodrich; A Rana Bayakly; Christina A Clarke; Glenn Copeland; Jack L Finch; Mary Lou Fleissner; Marc T Goodman; Amy Kahn; Lori Koch; Charles F Lynch; Margaret M Madeleine; Karen Pawlish; Chandrika Rao; Melanie A Williams; David Castenson; Michael Curry; Ruth Parsons; Gregory Fant; Monica Lin
Journal:  JAMA       Date:  2011-11-02       Impact factor: 157.335

10.  Risk of lymphoma subtypes after solid organ transplantation in the United States.

Authors:  C A Clarke; L M Morton; C Lynch; R M Pfeiffer; E C Hall; T M Gibson; D D Weisenburger; O Martínez-Maza; S K Hussain; J Yang; E T Chang; E A Engels
Journal:  Br J Cancer       Date:  2013-06-11       Impact factor: 9.075

View more
  63 in total

1.  High-dose chemotherapy and autologous stem cell transplant in elderly patients with primary CNS lymphoma: a pilot study.

Authors:  Elisabeth Schorb; Benjamin Kasenda; Gabriele Ihorst; Florian Scherer; Julia Wendler; Lisa Isbell; Heidi Fricker; Juergen Finke; Gerald Illerhaus
Journal:  Blood Adv       Date:  2020-07-28

2.  Improved survival in primary central nervous system lymphoma up to age 70 only: a population-based study on incidence, primary treatment and survival in the Netherlands, 1989-2015.

Authors:  M van der Meulen; A G Dinmohamed; O Visser; J K Doorduijn; J E C Bromberg
Journal:  Leukemia       Date:  2017-04-28       Impact factor: 11.528

3.  Incidence and survival of primary central nervous system lymphoma (PCNSL): results from the Girona cancer registry (1994-2013).

Authors:  R Fuentes-Raspall; M Solans; C Auñon-Sanz; M Saez; R Marcos-Gragera
Journal:  Clin Transl Oncol       Date:  2018-05-23       Impact factor: 3.405

4.  Comprehensive approach to diagnosis and treatment of newly diagnosed primary CNS lymphoma.

Authors:  Christian Grommes; James L Rubenstein; Lisa M DeAngelis; Andres J M Ferreri; Tracy T Batchelor
Journal:  Neuro Oncol       Date:  2019-02-19       Impact factor: 12.300

5.  Fluorescein sodium-guided biopsy or resection in primary central nervous system lymphomas with contrast-enhancing lesion in MRI.

Authors:  Fu-Hua Lin; Xiang-Heng Zhang; Ji Zhang; Zhen-Qiang He; Hao Duan; Chao Ke; Ke Sai; Xiao-Bing Jiang; Fuad Al-Nahari; Shao-Yan Xi; Yong-Gao Mou
Journal:  J Neurooncol       Date:  2018-08-16       Impact factor: 4.130

6.  Accuracy of apparent diffusion coefficients and enhancement ratios on magnetic resonance imaging in differentiating primary cerebral lymphomas from glioblastoma.

Authors:  Shayan Sirat Maheen Anwar; Mirza Zain Baig; Altaf Ali Laghari; Fatima Mubarak; Muhammad Shahzad Shamim; Umaima Ayesha Jilani; Muhammad Usman Khalid
Journal:  Neuroradiol J       Date:  2019-06-12

7.  Therapy and outcomes of primary central nervous system lymphoma in the United States: analysis of the National Cancer Database.

Authors:  Jaleh Fallah; Lindor Qunaj; Adam J Olszewski
Journal:  Blood Adv       Date:  2016-11-30

8.  Freiburg Neuropathology Case Conference : A Progressive Lesion of the Optic Tract, Brainstem, Hypothalamus and Basal Ganglia.

Authors:  C A Taschner; S Doostkam; P C Reinacher; H Urbach; A Rau; M Prinz
Journal:  Clin Neuroradiol       Date:  2019-12       Impact factor: 3.649

9.  Primary central nervous system lymphoma: is whole-body CT and FDG PET/CT for initial imaging reasonable?

Authors:  Hana Malikova
Journal:  Quant Imaging Med Surg       Date:  2019-09

Review 10.  Central Nervous System Involvement in Peripheral T Cell Lymphoma.

Authors:  Dai Chihara; Yasuhiro Oki
Journal:  Curr Hematol Malig Rep       Date:  2018-02       Impact factor: 3.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.